Free Trial

Perspective Therapeutics (CATX) News Today

Perspective Therapeutics logo
$2.26 -0.18 (-7.20%)
As of 02:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Perspective Therapeutics, Inc. stock logo
JPMorgan Chase & Co. Boosts Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX)
JPMorgan Chase & Co. raised its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 498.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 149,045 shares of the company's stock after buying an additional 124,133 s
Perspective Therapeutics, Inc. stock logo
Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Recommendation of "Buy" by Brokerages
Shares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have been assigned an average recommendation of "Buy" from the eleven analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating, seven have given a buy rating and three hav
Perspective Therapeutics, Inc. stock logo
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Marshall Wace LLP
Marshall Wace LLP lessened its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 45.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 807,172 shares of the company's stock after selling 683,619 shares durin
Perspective Therapeutics, Inc. stock logo
215,725 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Bought by Jump Financial LLC
Jump Financial LLC bought a new stake in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 215,725 shares of the company's stock, valued at approximately
Perspective Therapeutics, Inc. stock logo
Walleye Capital LLC Purchases 457,675 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)
Walleye Capital LLC boosted its position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 2,526.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 475,792 shares of the compa
Perspective Therapeutics, Inc. stock logo
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Altium Capital Management LLC
Altium Capital Management LLC decreased its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 68.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 92,224 sh
Perspective Therapeutics, Inc. stock logo
Affinity Asset Advisors LLC Acquires 800,000 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)
Affinity Asset Advisors LLC raised its holdings in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 160.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,300,000 shares of the c
Perspective Therapeutics, Inc. stock logo
Perspective Therapeutics (NYSE:CATX) Price Target Cut to $10.00 by Analysts at Truist Financial
Truist Financial decreased their price objective on shares of Perspective Therapeutics from $21.00 to $10.00 and set a "buy" rating for the company in a research note on Monday.
Perspective Therapeutics, Inc. stock logo
Equities Analysts Issue Forecasts for CATX Q2 Earnings
Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Research analysts at HC Wainwright raised their Q2 2025 EPS estimates for shares of Perspective Therapeutics in a research note issued to investors on Monday, March 31st. HC Wainwright analyst R. Burns now anticipates that the company wil
Perspective Therapeutics, Inc. stock logo
Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of "Buy" by Analysts
Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the twelve analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, eight have assigned a buy recommenda
Perspective Therapeutics, Inc. stock logo
Perspective Therapeutics, Inc. (NYSE:CATX) CEO Purchases $49,338.24 in Stock
Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) CEO Johan M. Spoor acquired 22,026 shares of the firm's stock in a transaction that occurred on Friday, March 28th. The stock was bought at an average price of $2.24 per share, with a total value of $49,338.24. Following the completion of the acquisition, the chief executive officer now directly owns 59,383 shares of the company's stock, valued at $133,017.92. This trade represents a 58.96 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Perspective Therapeutics, Inc. stock logo
Robert F. Williamson III Purchases 22,192 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) Stock
Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) Director Robert F. Williamson III bought 22,192 shares of the stock in a transaction on Friday, March 28th. The stock was purchased at an average price of $2.27 per share, for a total transaction of $50,375.84. Following the completion of the purchase, the director now owns 70,837 shares of the company's stock, valued at approximately $160,799.99. This trade represents a 45.62 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Perspective Therapeutics, Inc. stock logo
Perspective Therapeutics, Inc. (NYSE:CATX) CFO Juan Graham Acquires 33,333 Shares
Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) CFO Juan Graham purchased 33,333 shares of the firm's stock in a transaction that occurred on Friday, March 28th. The stock was bought at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the transaction, the chief financial officer now directly owns 35,354 shares of the company's stock, valued at $79,546.50. This trade represents a 1,649.33 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.
Perspective Therapeutics, Inc. stock logo
Perspective Therapeutics, Inc. (NYSE:CATX) Director Buys $81,630.30 in Stock
Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) Director Robert F. Williamson III purchased 38,145 shares of Perspective Therapeutics stock in a transaction on Monday, March 31st. The shares were acquired at an average cost of $2.14 per share, for a total transaction of $81,630.30. Following the completion of the transaction, the director now owns 108,982 shares of the company's stock, valued at $233,221.48. This represents a 53.85 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Perspective Therapeutics, Inc. stock logo
Perspective Therapeutics (NYSE:CATX) Earns Buy Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a report on Monday.
Perspective Therapeutics, Inc. stock logo
CATX Q1 EPS Forecast Lowered by Brookline Capital Management
Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Research analysts at Brookline Capital Management reduced their Q1 2025 earnings estimates for shares of Perspective Therapeutics in a research note issued to investors on Wednesday, March 26th. Brookline Capital Management analyst K. Dol
Perspective Therapeutics, Inc. stock logo
Research Analysts Issue Forecasts for CATX Q1 Earnings
Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Lifesci Capital issued their Q1 2025 earnings per share estimates for Perspective Therapeutics in a research report issued to clients and investors on Thursday, March 27th. Lifesci Capital analyst D. Kennedy anticipates that the company w
Perspective Therapeutics management to meet with Oppenheimer
Perspective Therapeutics, Inc. stock logo
Royal Bank of Canada Has Lowered Expectations for Perspective Therapeutics (NYSE:CATX) Stock Price
Royal Bank of Canada decreased their target price on Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating for the company in a research note on Thursday.
Perspective Therapeutics, Inc. stock logo
Perspective Therapeutics (NYSE:CATX) Earns Outperform Rating from Wedbush
Wedbush restated an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Wednesday.
Perspective Therapeutics, Inc. stock logo
What is HC Wainwright's Estimate for CATX FY2025 Earnings?
Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Equities research analysts at HC Wainwright dropped their FY2025 earnings per share estimates for shares of Perspective Therapeutics in a research note issued on Wednesday, March 19th. HC Wainwright analyst R. Burns now anticipates that t
Perspective Therapeutics, Inc. stock logo
HC Wainwright Reiterates "Buy" Rating for Perspective Therapeutics (NYSE:CATX)
HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Perspective Therapeutics in a report on Wednesday.
Perspective Therapeutics, Inc. stock logo
Perspective Therapeutics (CATX) Expected to Announce Quarterly Earnings on Wednesday
Perspective Therapeutics (NYSE:CATX) will be releasing earnings after the market closes on Wednesday, March 26, Financial Modeling Prep reports.
Perspective Therapeutics, Inc. stock logo
Perspective Therapeutics' (CATX) Outperform Rating Reiterated at Wedbush
Wedbush reaffirmed an "outperform" rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Monday.
Perspective Flat on New Drug Trials
Perspective Therapeutics, Inc. stock logo
Brokers Set Expectations for CATX Q4 Earnings
Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Analysts at HC Wainwright issued their Q4 2024 earnings per share estimates for Perspective Therapeutics in a report issued on Thursday, March 13th. HC Wainwright analyst R. Burns forecasts that the company will earn ($0.24) per share for
Perspective Therapeutics, Inc. stock logo
Perspective Therapeutics (NYSE:CATX) Now Covered by HC Wainwright
HC Wainwright started coverage on Perspective Therapeutics in a research report on Thursday. They set a "buy" rating and a $10.00 target price on the stock.
Get Perspective Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter.

CATX Media Mentions By Week

CATX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CATX
News Sentiment

1.21

0.69

Average
Medical
News Sentiment

CATX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CATX Articles
This Week

4

4

CATX Articles
Average Week

Get Perspective Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NYSE:CATX) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners